Related Experiment Video
Updated: Mar 17, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.4K
Rough Set Theory as an Interpretable Method for Predicting the Inhibition of Cytochrome P450 1A2 and 2D6.
Julien Burton1, Joachim Petit2,3, Emeric Danloy1
1Laboratoire de Physico-Chimie Informatique, Groupe de Chimie Physique Théorique et Structurale, University of Namur (FUNDP), 61 rue de Bruxelles, B-5000 Namur, Belgium phone: +32 (0)81 72 45 34; fax:+32 (0)81 72 54 66.
Molecular Informatics
|August 3, 2016
Summary
This study introduces a novel data mining approach using Rough Set Theory (RST) to predict drug-drug interactions mediated by cytochrome P450 (CYP) enzymes. The method accurately identifies molecular fragments associated with CYP inhibition, aiding drug discovery.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Predicting drug metabolism and interactions is crucial in drug discovery.
- Cytochrome P450 (CYP) enzymes mediate significant drug-drug interactions.
- Early identification of potential inhibitors is a key challenge.
Purpose of the Study:
- To develop a predictive model for CYP1A2 and CYP2D6 inhibition using a novel data mining approach.
- To identify structure-activity relationships associated with CYP inhibition.
- To assess the utility of Rough Set Theory (RST) in predicting drug interactions.
Main Methods:
- Coupling Rough Set Theory (RST) with molecular structural descriptions (MACCS keys and in-house fingerprints).
- Utilizing extracted RST rules as classifiers for independent molecular sets.
- Analyzing rule-building fragments to identify key structural features related to CYP inhibition.
Main Results:
- Achieved high prediction accuracies: 90.6% for CYP1A2 and 88.2% for CYP2D6.
- Identified specific molecular fragments strongly correlated with CYP inhibition.
- Demonstrated the effectiveness of RST in building predictive models for drug interactions.
Conclusions:
- Rough Set Theory (RST) is a suitable tool for developing predictive models of CYP inhibition.
- The approach successfully infers structure-activity rules linked to drug potency.
- This method aids in understanding molecular mechanisms of drug-drug interactions.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
99
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
99
01:25Pharmacokinetics: Drug–Drug Interactions
606
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
606
01:17Drug Metabolism: Phase I Reactions
5.5K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
5.5K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
368
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
368
01:16Protein-Drug Binding: Mechanism and Kinetics
2.0K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K
01:16Drug toxicity: Idiosyncratic Reactions
114
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
114